← Leaderboards
Jie Wu
University Of South Florida
$6,950,728
Attributed
$9,785,647
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $994.9K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,785,647 · 8
By mechanism
R01$7,291,313 · 4
P01$1,395,005 · 1
R29$412,478 · 1
R21$396,540 · 1
R56$290,311 · 1
Top collaborators
- Blaine H. M. Mooers5 shared
- Herman O Sintim4 shared
- Vivek Subbiah4 shared
- Funda Meric-Bernstam3 shared
- Jordi Rodon Ahnert2 shared
Most similar at University Of South Florida
Same institution · by research overlap
- Steven Brem$1,603,741
- William S. Dalton$20,173,582
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationMalignant NeoplasmsMutantProtein Tyrosine KinaseCancer TherapySignal TransductionTumorAnimalsSolid NeoplasmOncogenesPharmaceutical PreparationsOncogenicPropertyCancer PatientBaseLung NeoplasmsIn VivoTransgenic MiceProtein Tyrosine PhosphataseCell LineMediatingGenesEpidermal Growth FactorCells
Grant awards (31)
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold$580,663
R01 · FY2025 · CA · contact PI
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold$551,629
R01 · FY2024 · CA · contact PI
Blocking tumor progression in therapy-responsive RET aberration-associated cancer$369,899
R01 · FY2024 · CA · contact PI
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold$567,912
R01 · FY2023 · CA · contact PI
Blocking tumor progression in therapy-responsive RET aberration-associated cancer$382,199
R01 · FY2023 · CA · contact PI
Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold$612,099
R01 · FY2022 · CA · contact PI
Blocking tumor progression in therapy-responsive RET aberration-associated cancer$382,759
R01 · FY2022 · CA · contact PI
Blocking tumor progression in therapy-responsive RET aberration-associated cancer$391,096
R01 · FY2021 · CA · contact PI
Blocking tumor progression in therapy-responsive RET aberration-associated cancer$414,123
R01 · FY2020 · CA · contact PI
Roles of PTPN11 in regulating and driving epithelial cancer$307,100
R01 · FY2017 · CA · contact PI
Roles of PTPN11 in regulating and driving epithelial cancer$307,100
R01 · FY2016 · CA · contact PI
Roles of PTPN11 in regulating and driving epithelial cancer$307,100
R01 · FY2015 · CA · contact PI
Roles of PTPN11 in regulating and driving epithelial cancer$339,149
R01 · FY2014 · CA · contact PI
Modeling the KIF5B-RET Fusion Gene of Lung Cancer in Vivo$213,296
R21 · FY2014 · CA · contact PI
Roles of PTPN11 in regulating and driving epithelial cancer$349,638
R01 · FY2013 · CA · contact PI
Modeling the KIF5B-RET Fusion Gene of Lung Cancer in Vivo$183,244
R21 · FY2013 · CA · contact PI
Development of SHP2-selective Phosphatase Inhibitors for Cancer Therapy$275,505
P01 · FY2011 · CA · contact PI
Development of SHP2-selective Phosphatase Inhibitors for Cancer Therapy$297,067
P01 · FY2010 · CA · contact PI
Development of SHP2-selective Phosphatase Inhibitors for Cancer Therapy$290,828
P01 · FY2009 · CA · contact PI
Modulation of ErbB Signaling$290,311
R56 · FY2009 · CA · contact PI
Development of SHP2-selective Phosphatase Inhibitors for Cancer Therapy$269,731
P01 · FY2008 · CA · contact PI
Modulation of ErbB Signaling$275,105
R01 · FY2007 · CA · contact PI
Development of SHP2-selective Phosphatase Inhibitors for Cancer Therapy$261,874
P01 · FY2007 · CA · contact PI
Modulation of ErbB Signaling$283,322
R01 · FY2006 · CA · contact PI
Modulation of ErbB Signaling$290,140
R01 · FY2005 · CA
Modulation of ErbB Signaling$290,140
R01 · FY2004 · CA
Modulation of ErbB Signaling$290,140
R01 · FY2003 · CA
SIGNAL TRANSDUCTION BY LYSOPHOSPHATIDIC ACID$107,735
R29 · FY2003 · CA
SIGNAL TRANSDUCTION BY LYSOPHOSPHATIDIC ACID$104,598
R29 · FY2002 · CA
SIGNAL TRANSDUCTION BY LYSOPHOSPHATIDIC ACID$101,551
R29 · FY2001 · CA
SIGNAL TRANSDUCTION BY LYSOPHOSPHATIDIC ACID$98,594
R29 · FY2000 · CA